TRK Inhibitors: Clinical Development of Larotrectinib
Authors:
- 4 February 2019
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 21 (2) , 14
Abstract
In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK fusion-positive tumors.Keywords
This publication has 40 references indexed in Scilit:
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerNature Medicine, 2013
- Brain-Derived Neurotrophic Factor/Tyrosine Kinase B Signaling Regulates Human Trophoblast Growth in an in Vivo Animal Model of Ectopic PregnancyEndocrinology, 2011
- Rearrangements of NTRK1 gene in papillary thyroid carcinomaMolecular and Cellular Endocrinology, 2010
- Regulation of preimplantation embryo development by brain-derived neurotrophic factorDevelopmental Biology, 2007
- Neurotrophin signaling: many exciting surprises!Cellular and Molecular Life Sciences, 2006
- TrkA alternative splicingCancer Cell, 2004
- Cryptic t(12;15)(p13;q26) producing the ETV6-NTRK3 fusion gene and no loss of IGF2 imprinting in congenital mesoblastic nephroma with trisomy 11Cancer Genetics and Cytogenetics, 2002
- A novel ETV6-NTRK3 gene fusion in congenital fibrosarcomaNature Genetics, 1998
- The trk proto-oncogene encodes a receptor for nerve growth factorCell, 1991
- Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGFNature, 1991